GHRP-2 — Literature-Reported Ranges & Study Protocols

Read this first

Every figure on this page is a range reported in published literature or in a publicly documented study protocol. It is a record of what researchers used, not a recommendation, a therapeutic protocol, or advice. Peptide Intel Hub is an independent publication, sells nothing, and describes these compounds as in-vitro research reagents only.

Compound at a glance

Class: Hexapeptide GH secretagogue
Reported half-life: Approximately 30 minutes
Routes used in the literature: Intravenous in diagnostic use; subcutaneous in research designs
Also written as: Pralmorelin

What the published studies reported

Each row below describes one body of work. The model and population are part of the figure — a rodent per-kilogram quantity and a human trial quantity are not comparable.

Registered diagnostic testing

Reported quantity: 100 µg intravenously as a bolus
Frequency: Single administration
Study duration: Sampling at 15, 30, 45 and 60 minutes

This is a licensed diagnostic figure, not a multi-week protocol.

Paediatric and adult dose-ranging

Reported quantity: 0.1–1.0 µg/kg
Frequency: Single administration per test
Study duration: 60–120 minutes of sampling

GH response saturates toward the top of this window.

Multi-week appetite and IGF-1 research arms

Reported quantity: Around 100 µg per administration
Frequency: One to three times daily
Study duration: 2–16 weeks

Appetite stimulation is a consistent reported feature across these arms.

Dosage chart

These figures match the published chart for this compound on peptidedosages.com, including the reconstitution volume, resulting concentration, insulin-syringe units and the staged schedule. Educational reference only — not instructions, and not medical advice.

GHRP-2 · 10 mg Vial

GHRP-2 is dosed at 100 mcg–300 mcg daily via subcutaneous injection in educational protocols. A 10 mg vial reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.

Reconstitute: Add 3.0 mL bacteriostatic water → ~ 3.33 mg/mL concentration.
Typical daily range: 100–300 mcg once daily (gradual titration).
Easy measuring: At 3.33 mg/mL, 1 unit ≈ 33.3 mcg on a U‑100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Week	Daily Dose (mcg)	Units (per injection) (mL)
Weeks 1–2	100 mcg (0.1 mg)	3 units (0.03 mL)
Weeks 3–4	150 mcg (0.15 mg)	4.5 units (0.045 mL)
Weeks 5–8	200 mcg (0.2 mg)	6 units (0.06 mL)
Weeks 9–12 (optional)	250–300 mcg (0.25–0.3 mg)	7.5–9 units (0.075–0.09 mL)

Source chart on peptidedosages.com

Mixed with 3 ml of bacteriostatic water

The same arithmetic for every vial size GHRP-2 is supplied in, using a fixed 3 ml of bacteriostatic water. One unit on a U-100 insulin syringe is 0.01 ml, so the unit column below is simply the volume that carries the reported amount. Educational arithmetic only — not instructions, and not medical advice.

GHRP-2 · 3 ml bacteriostatic water

Vial size	Concentration	Per 1 unit	100 mcg =	300 mcg =
5 mg	1.67 mg/ml	17 mcg	6.0 units	18 units
10 mg	3.33 mg/ml	33 mcg	3.0 units	9.0 units

Unit columns use the range reported for this compound (100 mcg–300 mcg). Only the vial sizes this compound is actually supplied in are shown, and every figure assumes exactly 3 ml of bacteriostatic water. For any other volume, use the reconstitution calculator.

Reconstitution maths

A 5 mg vial in 2.5 mL of bacteriostatic water gives 2 mg/mL; 0.05 mL draws 100 µg.

Open the reconstitution calculator

How to read these figures

Diagnostic single-administration figures are frequently misquoted online as ongoing schedules.
Cortisol and prolactin rise alongside GH, as with GHRP-6.
Receptor desensitisation applies to the whole hexapeptide class.

Sources and citations

These are the published records the figures on this page are drawn from. Each one describes what researchers administered, in which model or population, and over what period. Quantities reported in a study are specific to that study's design and are not transferable guidance.

[1]
GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults
Popovic V, Leal A, Micic D, et al. · European Journal of Endocrinology · 2001 · PMID 11322505
Older men and women with decreased GH secretion received acute and chronic GHRP-2 administration to assess GH/IGF-1 responses compared with GHRH.
View the record
[2]
A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency
Bonert VS, Kennedy L, Michalik JL, et al. · Journal of Endocrinological Investigation · 2007 · PMID 17609397
Seventy-seven healthy subjects and GH-deficient adults were given a validated intravenous 1 microgram/kg GHRP-2 bolus dose as a diagnostic stimulation test for GH deficiency.
View the record
[3]
Growth hormone-releasing effect of oral growth hormone-releasing peptide 2 in children with short stature
Mericq V, Cassorla F, Bowers CY, et al. · European Journal of Endocrinology · 1998 · PMID 9661608
GH-deficient children were treated for eight months with graded doses of a GH-releasing peptide to evaluate sustained GH secretion and growth effects.
View the record

Search the databases yourself

Read the GHRP-2 research brief

Other growth hormone compounds

AOD-9604hGH fragment 176-191 CJC-1295 (no DAC)Tetra-substituted GHRH (1-29) analogue CJC-1295 (no DAC) + IpamorelinGHRH analogue + selective ghrelin-receptor agonist blend CJC-1295 with DACGHRH analogue with albumin-binding drug affinity complex

All research protocols

Peptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.